
Dr. Usmani on Future Research Directions for Nirogacestat/Teclistamab in Myeloma
Saad Z. Usmani, MD, FACP, discusses future research directions with the combination of nirogacestat and teclistamab in patients with relapsed/refractory multiple myeloma.
Saad Z. Usmani, MD, FACP, chief of Plasma Cell Disorders and director of Clinical Research in Hematologic Malignancies, Levine Cancer Institute, Atrium Health, discusses future research directions with the combination of nirogacestat (PF-03084014) and teclistamab (JNJ-64007957) in patients with relapsed/refractory multiple myeloma.
Recently,
If the combination demonstrates positive safety and is shown to enhance clinical activity, it is likely that the next steps with this research would be to examine nirogacestat and teclistamab in combination with other therapies, Usmani concludes.



































